@

Protein Profiling Platform - Quality Assurance

High quality standards are essential for robust and reliable Biomarker Discovery and Verification as well as for the discovery of new Drug Targets. During the last 10 years a stringent quality assurance workflow has been established for our Antibody Array Platform in order to conduct immuno-based biomedical discovery studies with excellent standards in terms of reproducibility and platform stability. The automated assay workflow further improves the performance of our service. 

 

Biomarker Discovery Phase - scioDiscover Platform

  • Stringent antigen design for maximised specificity of the resulting antibodies
  • Antibodies are antigen affinity-purified
  • Targets identified through transcriptional studies and expert input
  • Stringent QC management
  • Features:  
    • cross-species activity (human and mouse for high versatility)
    • detection of several protein isoforms
    • cost-efficiency through high content

  

Verification Phase - Custom Array Platform

  • Stringent antigen design for maximised specificity of the resulting antibodies
  • Antibodies are antigen affinity-purified
  • In-house QC on Western Blot (different cell lines or tissues) and optional ELISA-based tests
  • In-house QC on large-scale protein arrays (> 9.000 human proteins)
  • In-depth validation of array performance
  • Definition of biomarker signature with highest accuracy
  • Selection of appropriate binders / sandwich pairs
  • Features:  
    • specifically designed antibodies for further use in diagnostic assays
    • fully renewable antibody formats
    • in-depth quality controlled (WB, ELISA)
    • comprehensive cross-reactivity profile (large-scale protein arrays)

 

Orthogonal Biomarker Validation

Verified Candidates can be further validated by orthogonal methods according to customer’s requirements

  • Western Blotting ( WB )
  • ELISA
  • Immuno-Precipitation ( IP )
  • Mass spectrometry ( MS )
  • Biacore

 

Overview
Scio-Discover
    Biomarker
Discovery
    Custom Microarrays
for Biomarker Verification
    Contact
us

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1,300 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels…
Read more
scioDiscover - Protein Profiling on expression level

scioDiscover - Protein Profiling on expression level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell surface marker and Cytokine profiling

scioCD - Cell surface marker and Cytokine profiling

  Characterise a certain cell type?   Cell composition in a certain tissue sample?   In-depth profiling of CD-marker expression?   Increase your throughput at high sensitivity levels? You aim…
scioUbi

scioUbi

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay.   Features Screen…
scioCyto : Cytokine profiling

scioCyto : Cytokine profiling

scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or…

COVID-19 related activities and services

covid 19 portfolio web

News

New article | Prevention of Cyclosp.-A mediated anemia and peritubular loss

| June 2022 | In a study by Robert Labes et al. insights in prevention of cyclosporine mediated anemia and peritubular capillary loss were identified.

Labes, R. et al. Daprodust. prevents cyclosp.-A mediated anemia and peritubular capillary loss. Kidney International 2022 in press.
New article | The Lifestyle Modifications Affect the Endometrial Proteome

| June 2022 | In a study by D. Abdulkhalikova et al. Endometrial Proteome changes werde identified impacted by Lifestyle modification in woman with Polycystic Ovarian Syndrome and Obesity.

Abdulkhalikova, DR. et al. The Lifestyle Modifications and Endometrial Proteome Changes of Women With Polycystic Ovary Syndrome and Obesity. Front. Endocrinol. 2022 in press.
New article | Cycle-dependent biomarkers in endometriosis

| May 2022 | In a study by Maja Pušić et al. Cycle-dependent plasma protein biomarkers for peritoneal endometriosis were identified by our scioDiscover platform.

Pušić, M. et al. Antibody Arrays Identified Cycle-Dependent Plasma Biomarker Candidates of Peritoneal Endometriosis. J. Pers. Med. 202212, 852.
New article | Co-Expression of microRNAs and Proteins in Alzheimer’s Disease

| Jan 2022 | In a study by Valentina di Pietro at Birmingham University our scioDoiscover platform was used to analyse the co-expression of proteins and microRNAs in the brains of Alzheimer's disease patients.

Watson, C. N. et al. Co-Expression Analysis of microRNAs and Proteins in Brain of Alzheimer’s Disease Patients. Cells 11, 163 (2022).
New article | ETV6 levels predict outcome in DLBCL

| Jan 2022 | Erich Piovan and collegues at University of Padua collaborated with Sciomics to study specific biomarkers in FFPE tissue samples of DLBCL patients by custom antibody microarrays.

Marino, D. et al. High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients. Cancers 14, (2022).

Testimonials

Dr. Bettina Grötsch

Department of Medicine 3 - Rheumatology and Immunology, University Clinics Erlangen, Erlangen, Germany

"Our lab is working with human osteoclast that were isolated and differentiated from human peripheral blood. Therefore, we were quite limited in cell numbers and protein content for our planned Phosphoprotein analyses. Nonetheless, Sciomics and especially Camille Lowy helped us a lot to test and improve our protein isolation techniques to achieve some interesting phosphoproteome data in human osteoclasts. We were really impressed by the detailed data report and their willingness to discuss and reanalyze the data repeatedly until we got the best results out of our measurements. Even several month after their first report, we could ask for help and suggestions with an immediate reply.  The phosphoproteome analyses completed our preliminary project data and are now published in Frontiers Immunology.  Altogether, we were very happy with the service of Sciomics and special thanks to Camille Lowy and Christoph Schröder who guided us through the whole process."

Product: scioPhospho
Publication: Grötsch B. et al. 2022 Front. Immunol. 13:958974 

Alenka Djarmila Behsen, PhD candidate

Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway

"The process of working with Ronny and his colleagues at Sciomics has been very easy and efficient. Response time is very quick and they are always available for meetings when you have more questions. Would definitely recommend working with Sciomics."

Product: scioCD

 

Tweets

  • 34 days ago

    RT @BioRNCluster: 🎉🎉So excited to be part of @EBDgroup #BioEurope! A great feeling after the long break. 👉The list of our members there is…

  • 38 days ago

    RT @BioRNCluster: Short update from #Leuven 🇧🇪: 2nd 🛑 at #LISC. outstanding presentation and tour of the single cell omics facilities. BRIL…

  • 42 days ago

    Yesterday, we had a session dedicated to the activities of our Transcan-2 consortium #BioEndoCar striving to achiev… https://t.co/86y3C4vZAv

  • 42 days ago

    Last day of the 46th Annual Meeting of the International Society of Oncology and Biomarkers. #ISOBM2022 We got a p… https://t.co/trLJYc6m12

  • 42 days ago

    RT @car_endo: #ISOBM 2022 is almost over. We enyojed some really interesting talks at #BioEndoCar session: Omics technology to improve canc…